Enhancement of chemosensitivity by tyrphostin AG825 in high-p185neu expressing non-small cell lung cancer cells

Cancer Research

Volumn 56, Issue 5, 1996, Pages 1068-1074

  Tsai, Chun Ming ^a,b   Levitzki, Alexander ^c   Wu, Li Hwa ^b   Chang, Kuo Ting ^b   Cheng, Chia Chien ^b   Gazit, Aviv ^c   Perng, Reury Perng ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; PROTEIN TYROSINE KINASE; TYRPHOSTIN;

ANIMAL CELL; ARTICLE; CELL CYCLE G2 PHASE; CELL SURVIVAL; CHEMOSENSITIVITY; DNA DAMAGE; DRUG EFFECT; DRUG INDUCED DISEASE; ENZYME ACTIVITY; GENETIC CODE; GENETIC REGULATION; GENETIC TRANSCRIPTION; IMAGE ENHANCEMENT; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION;

BENZOTHIAZOLES; BENZYLIDENE COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; DRUG RESISTANCE; HUMANS; LUNG NEOPLASMS; NITRILES; PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 0030044628     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Coussens, L , Yang-Feng, T. L , Liao, Y. C , Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T , Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene Science (Washington DC), 230: 1132-1139, 1985
2. Parsons, J. T., and Parsons, S. J Protein-tyrosine kinases, oncogenes, and cancer In: V. T. DeVita, Jr , S Hellman, and S A. Rosenberg (eds.), Important Advances in Oncology, pp 3-18 Philadelphia: J B Lippincott Co , 1993,
3. Slamon, D J , Godolphin, W., Jones, L. A , Holt, J. A , Wong, S G., Keith, D. E., Levin, W. J., Stuart, S. G , Udove, J., Ullrich, A., and Press, M. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science (Washington DC), 244: 707-712, 1989.
4. Kameda, T., Yasui, W , Yoshida, K., Tsujino, T , Nakayama, H., Ito, M., Ito, H., and Tahara, E. Expression of ERBB2 in human gastric carcinomas relationship between p185ERBB2 expression and the gene amplification. Cancer Res , 50: 8002-8009, 1990.
5. Schneider, P. M , Hung, M. C., Chiocca, S. M , Manning, J , Zhao, X., Fang, K., and Roth, J. A Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res., 49. 4968-4971, 1989
6. neu expression in human lung adenocarcinomas predicts shortened survival Cancer Res., 50: 5184-5191, 1990
7. Tateishi, M., Ishida, T , Mitsudomi, T , Kaneko, S , and Sugimachi, K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur. J. Cancer, 27: 1372-1375, 1991
8. Tsai, C M., Chang, K. T., Perng, R P., Mitsudomi, T , Chen, M. H., Kadoyama, C., and Gazdar, A F Correlation of intrinsic chemoresistance of non-small cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J. Natl Cancer Inst , 85: 897-901, 1993.
9. Tsai, C. M., Chang, K. T , Wu, L. H., Chen, J. Y., Gazdar, A. F., Mitsudomi, T., Chen, M. H , and Perng, R. P. Correlations between intrinsic chemoresistance and HER-2/neu gene expression: p53 gene mutations and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res., 56: 206-209, 1996
10. neu in the HER-2/neu transfected human lung cancer cells. J. Natl. Cancer Inst , 87: 682-684, 1995
11. Padiella, A., Lehvaslaiho, H., Magni, M., Alitalo, K , and Meldolesi, J. Activation of an EGFR/neu chimeric receptor: early intracellular signals and cell proliferation responses. Oncogene, 4: 1299-1305, 1989.
12. Peles, E , Ben-Levy, R., Or, E., Ullrich, A., and Yarden, Y. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase Cγ. EMBO J., 10. 2077-2086, 1991
13. neu expressing human non-small cell lung cancer cell lines. J. Natl. Cancer Inst., 86: 1018-1020, 1994.
14. Schlegel, R., and Pardee, A. Caffeine induced uncoupling of mitosis from the completion of DNA replication in mammalian cells Science (Washington DC), 232: 1264-1266, 1986.
15. Fingen, H. J., Chang, J. D., and Pardee, A. B. Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alleviating agents. Cancer Res., 46. 2463-2467, 1986.
16. 2-arrest in Chinese hamster ovary cells treated with anticancer drugs. J. Natl. Cancer Inst., 57: 1139-1143, 1976.
17. 2 arrest in Chinese hamster ovary cells. Cancer Res., 50: 3761-3766, 1990.
18. cdc2 Cell, 68: 787-797, 1992.
19. Osherov, N., Gazit, A., Gilon, C., and Levitzki, A. Selective inhibition of the epidermal growth factor and HER-2/neu receptors by tyrphostins. J. Biol. Chem., 268: 11134-11142, 1993.
20. Levitzki, A., and Gazit, A Tyrosine kinase inhibition: an approach to drug development. Science (Washington DC), 267: 1782-1788, 1995.
21. Gazdar, A. F., Kadoyama, C., Venzon, D., Park, J. G., Tsai, C. M., Linnoila, R. I., Mulshine, J L., Ihde, D. C., and Giaccone, G. The effects of histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. Natl. Cancer Inst. Monogr , 13: 191-196, 1992.
22. Mitsudomi, T , Steinberg, S. M., Nau, M. M., Carbone, D , D'Amico, D., Bodner, S., Oie, H. K., Linnoila, R. I., Mulshine, J. L., Minna, J. D., and Gazdar, A. F. p53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene, 7: 171-180, 1992
23. Carney, W. P., Hamer, P. I., and Petit, D Detection and quantitation of the human neu oncoprotein. J. Tumor Marker Oncol , 6: 53-72, 1991.
24. Berenbaum, M. C. Synergy, additivism and antagonism in immunosuppression, a critical review Clin. Exp. Immunol., 28: 1-18, 1977.
25. Tsai, C. M., Shiao, S H , Frey, C. M., Chang, K. T., Perng, R. P., Gazdar, A. R. and Kramer, B. S Combination cytotoxic effects of cis-diamminedichloroplatinum(II) and 5-fluorouracil with and without leucovorin against human non-small cell lung cancer cell lines Cancer Res., 53: 1079-1084, 1993
26. Tsai, C. M., Gazdar, A F , Perng, R. P., and Kramer, B. S. Schedule dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines. Int. J. Cancer, 47: 401-407, 1991.
27. Chiu, J. H., Kao, H L., Wu, L. H., Chang, H. M., and Lui, W. Y. Prediction of relapse or survival after resection in human hepatomas by DNA flow cytometry J Clin. Invest., 89. 539-545, 1992.
28. Yu, D., Suen, T. C., Yan, D. H., Chang, L. S., and Hung, M. C. Transcriptional repression of the neu protooncogene by the adenovirus 5E1A gene products Proc. Natl. Acad. Sci. USA, 87: 4499-4503, 1990.
29. Draetta, G., Piwnica-Worms, H., Morrison, D., Druker, B., Roberts, T., and Beach, D. Human cdc2 protein kinase is a major cell-cycle regulated tyrosine kinase substrate. Nature (Lond.), 336: 738-744, 1988.
30. O'Connor, P. M., and Kohn, K. W. A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells. Semin. Cancer Biol., 3: 409-416, 1992.
31. Hartwell, L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell, 71: 543-546, 1992.
32. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
33. Lowe, S. W., Ruley, H. E., Jacks, T., and Houseman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
34. Fujiwara, T , Grimm, E. A., Mukhopadhyay, T., Zhang, W. W , Owen-Schaub, L. B., and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2291, 1994.
35. Kuerbitz, S. J., Plunkett, B S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following radiation. Proc Natl. Acad. Sci. USA, 89: 7491-7495, 1992
36. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J , Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
37. neu. Cancer Res., 56. 794-801, 1996.
38. c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res., 54: 3758-3765, 1994.
39. Pietras, R. J., Fendly, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B , and Slamon, D. J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene, 9: 1829-1838, 1994.
40. Huang, P , Chubb, S., Hertel, L W., Grindey, G. B., and Plunkett, W. Action of 2′,2′-difluoro-2′-deoxycytidine on DNA synthesis. Cancer Res., 51: 6110-6117, 1991
41. neu: a relationship between disruption of this regulation and transformation. Proc. Natl. Acad. Sci. USA, 92: 1092-1096, 1995.
42. Yu, D , Wang, S. S., Dulski, K. M., Tsai, C M , Nicolson, G. L., and Hung, M C. c-erbB2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties Cancer Res., 54: 3260-3266, 1994.
43. Press, M. F., Cordon-Cardo, C., and Slamon, D J. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene, 5: 953-962, 1990.